Repare Therapeutics ( (RPTX) ) just unveiled an update.
In January 2025, Repare Therapeutics announced a significant reorganization, including a 75% workforce reduction, to prioritize its Phase 1 clinical programs. This reorganization, approved on February 23, 2025, is expected to incur one-time costs of approximately $7.3 million for severance and $1.4 million for retention, with anticipated annual savings of $21 million. The departure of Chief Medical Officer Dr. Maria Koehler, effective March 31, 2025, is part of this restructuring, with severance benefits outlined. Retention bonuses are also being provided to key executives.
More about Repare Therapeutics
Repare Therapeutics Inc. operates in the biotechnology industry, focusing on the development of precision oncology medicines. The company’s primary products include clinical programs such as RP-1664, a PLK4 inhibitor, and RP-3467, a Polq ATPase inhibitor.
YTD Price Performance: -4.55%
Average Trading Volume: 480,019
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $53.56M
For detailed information about RPTX stock, go to TipRanks’ Stock Analysis page.